Parkinson’s disease is one of the most talked about and serious neurodegenerative diseases on earth. The disease already affects the lives of 10 million people worldwide. But now we have new research that suggests a possible treatment. This process involves non-neuronal cells and their transformation. Once they turn into neurons, they can remain in the brain and perform routine functions such as connecting with other nerve cells that make up nervous tissue, forming synapses, and distributing dopamine. These cells will help repair damage to dopaminergic cells from the disease.
Parkinson’s disease targets one area in the midbrain and affects the degeneration of neurons in that area. As a result, there is less dopamine left to feed the brain. Dopamine, being a neurotransmitter, affects the functioning and life of neurons.
The degeneration and gradual loss of dopaminergic neurons cause many mental and physical symptoms. These include stiffness, tremors and postural instability, which are symptoms of Parkinson’s disease. It can also show signs of depression, anxiety, memory loss, hallucinations, and dementia.
The research was carried out by Jeffrey Cordover, founding director of the ASU-Banner Neurodegenerative Disease Research Center at Arizona State University. study is published In the current issue of the journal Nature Regenerative Medicine.
A Press release released by Arizona State University that experimentally engineered cells were implanted in the brains of rats. These “designer” cells performed better for survival, development, neural connectivity and the production of dopamine.
The future approach will soon be put to the test in a clinical trial, the first of its kind, to be conducted on a specific population of Parkinson’s disease patients. To achieve the best results, this test will be carried out at various locations, including the Barrow Neurological Institute in Phoenix, where Cordover will serve as principal investigator. Such nerve grafting techniques aim to reverse the motor symptoms caused by Parkinson’s disease.
Cordover said in a statement that they were overjoyed at the prospect of being able to help people with this genetic form of Parkinson’s disease, but the lessons learned from this trial may also directly impact patients suffering from sporadic, or non-genetic Will have effect. , as a disease.